|
|
|
|
|
23.02.26 - 07:09
|
Almirall′s 2025 Results (Business Wire)
|
|
|
Almirall meets guidance for 2025, delivering 12.4% net sales growth and further pipeline progress, continuing its sustained growth trajectory with strong dermatology performance and commercial execution in Europe
Almirall delivered net sales growth in 2025 of 12.4% exceeding €1bn (total of €1,108.1MM), revenue increase of 12.5% (total of €1,114.5 MM), and EBITDA growth of 20.9% (total of €232.9 MM) – in line with its guidance and its sustained growth trajectory.
This revenue growth further advances Almirall's leadership in medical dermatology driven by the strong performance of its European dermatology business (+25.6% YoY increase to a total of €608 MM).
The continued strong performance of the biologics portfolio is the backbone of Almirall's growth, with Ilumetri® net sales increasing 12.3% YoY (total of €234.4 MM), and Ebglyss® net sales increasing more than 3x YoY to a total of €110.8 MM – reflecting its strong position and growth trajectory across Europe in the second year after...
|
|
|
|
|
|
|
|
|
|
|
10.11.25 - 07:33
|
Almirall′s 2025 9M Results (Business Wire)
|
|
|
Almirall continues its sustained growth trajectory in 9M 2025 - delivering 12.8% net sales growth, strong dermatology performance, solid commercial execution in Europe, and further pipeline progress
Sustained strong growth momentum with 12.8% Net Sales YoY increase to a total of €820.7 MM, with biologics continuing to deliver double-digit growth YoY and dermatology sales in Europe increasing 24.5% YoY further advancing Almirall´s leadership in medical dermatology.
EBITDA increase of 27.1% YoY in line with expectations, reaching a total of €180.7 MM. On track to meet 2025 guidance driven by biologics growth and operational strength.
Performance continues to be primarily driven by the biologics portfolio, with Ilumetri® net sales increasing 12.1% YoY (total of €170.9 MM), and Ebglyss® net sales of €75.5 MM – reflecting a more than 3x increase YoY as European markets are ramping up after launch.
Solid performance of the broad dermatology product portfolio with Wynzora® growing 32.4% YoY to a to...
|
|
|
07.08.25 - 08:03
|
Almirall and Absci Expand AI Drug Creation Collaboration Adding a Second Dermatology Target (GlobeNewswire EN)
|
|
|
BARCELONA, Spain and VANCOUVER, Wash., Aug. 07, 2025 (GLOBE NEWSWIRE) -- Almirall (BME: ALM), a global biopharmaceutical company focused on medical dermatology, and Absci Corporation (Nasdaq: ABSI), a clinical-stage biopharmaceutical company advancing breakthrough therapeutics with generative AI, today announced the expansion of their ongoing AI Drug Discovery collaboration with Almirall's selection of a second target aimed at dermatological indications....
|
|
|
|
|
|
|
25.07.25 - 07:15
|
Almirall H1 2025 Results (Business Wire)
|
|
|
Almirall Continues to Deliver on its Long-Term Growth Strategy with Net Sales Growth of 12.7% in H1 2025, Driven by a Strong European Dermatology Business and Increasing Biologics Sales
Solid growth trajectory maintained: H1 net sales increased by 12.7% to €560.5 million, with EBITDA reaching €121.8 million (+16.6% YoY), driven by the strong performance of the biologics portfolio and operational excellence.
Biologics as key growth drivers: Ebglyss® achieved net sales of €44.9 million (>4x YoY) across 14 European countries. Ilumetri® continued its steady growth with a 12.7% increase in sales YoY, totaling €113.3 million in H1.
Sustained strong performance in Europe: Almirall's broad product portfolio underpins its leadership in medical dermatology, led by continued growth of Wynzora® (€17.1 million, +32.6% YoY) and Klisyri® (€13.7 million, +25.7% YoY).
Full-year guidance 2025 and mid-term outlook confirmed: Double-digit net sales growth and EBITDA targets remain on track, supported by robu...
|
|
|
|
|
|
|
12.05.25 - 07:21
|
Almirall Q1 2025 Results (Business Wire)
|
|
|
Almirall delivers a strong start to 2025: growing Q1 overall sales by 15%, and 23.4% in its European Dermatology business YoY, aligned with the company's sustained growth trajectory
Continued strong growth trajectory with 15% Net Sales increase to a total of €284.6 MM with key products delivering high double-digit YoY growth and general medicines business aided by Q1 2025 out-licensing transaction.
EBITDA increase of 35.0% YoY in line with expectations to a total of €70.9 MM driven by continued strong operational execution including out-licensing income realized in Q1 2025.
Performance was driven by the biologics portfolio, with Ilumetri® showing 12.7% increase in sales vs Q1 2024 (total of €55.1 MM), and Ebglyss® delivering €19.4 MM quarterly sales - mainly achieved by the continued positive launch dynamics in Germany and growing contributions from recent launched countries.
The broad dermatology product portfolio continues its sustained growth including performance in line with expectations o...
|
|
|
|
|
06.03.25 - 08:12
|
Almirall Announces CFO Transition Plan and Appoints Jon U. Garay Alonso as CFO to Succeed Mike McClellan in August 2025 (Business Wire)
|
|
|
CFO transition plan focusses on business continuity and the company's strong growth trajectory as European leader in medical dermatology
Jon U. Garay Alonso has over 25 years of experience in business and finance in numerous leadership roles with increasing seniority in the pharma industry and other sectors
Mike McClellan will leave Almirall in September, after nearly six years as CFO, delivering a strong track and helping the company enter an era of sustained growth and profitability
BARCELONA, Spain--(BUSINESS WIRE)--Almirall, S.A. (ALM) a global biopharmaceutical company based in Barcelona, today announced the appointment of Jon U. Garay Alonso as Chief Financial Officer and member of the company's Management Board as of August 2025, succeeding Mike McClellan, who will leave the company in September 2025, after nearly six successful years as CFO.
This planned transition is focused on maintaining business continuity and enabling the organization to keep and further build its strong trajectory towards ...
|
|
|
|
|
|
|
24.02.25 - 07:03
|
Almirall 2024 Full-Year Results: Almirall Surpassed Guidance for 2024 - Entering an Era of Sustained Growth and Further Advancing Its Medical Dermatology Pipeline (Business Wire)
|
|
|
Almirall's net sales growth in 2024 was 10.2% YoY (total of €985.7 MM) with EBITDA growth of 10.6% YoY (total of €192.6 MM) – surpassing guidance for the year with all key growth drivers delivering double digit growth.
Company revenue growth continues to be driven by the strong performance of the European Dermatology business (+22.5% YoY, total sales of €484.1 MM), specifically biologics.
Ebglyss® achieved 34% growth in Q4 compared to Q3, delivering a total of €33.2 MM sales in 2024, mainly in Germany. The product is now available in 11 markets across Europe and continues to receive very positive feedback from dermatologists.
Ilumetri® continued its very strong growth trajectory with 25.5% sales increase YoY, delivering sales of €208.8 MM – based on continued market expansion and taking a higher share from competition.
Strong performance of Almirall´s broad dermatology portfolio: Wynzora® grew 53.3% YoY (total of €25.9 MM), and Klisyri® grew 17.8% YoY (total of €24.5 MM). Sustained...
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
